RBP5 and melanoma: developed a gene signature (CD79B, CD1D, CCR6, LAT, SKAP1, CETP, EIF1AY, RBP5, and PTGDS) associated with TLSs in melanoma patients, which predicted clinical outcomes of melanoma patients treated with ICI (35).